Session 96 - 12th CROI

Home

Session 96 Poster Abstracts
New Antiretroviral Agents: New Classes
Wednesday, 1:30 - 3:30 pm
Hall A

541	TAK-652, a Novel Small Molecule CCR5 Antagonist with Potent Anti-HIV-1 Activity Masanori Baba*¹, N Kanzaki², H Miyake², X Wang¹, K Takashima², K Teshima², M Shiraishi², and Y Iizawa² ¹Kagoshima Univ, Japan and ²Takeda Pharma Co, Osaka, Japan
542	TAK-652, a Novel Small Molecule Inhibitor of CCR5 Has Favorable anti-HIV Interactions with Other Antiretrovirals in vitro Cécile L Tremblay*¹, F Giguel², T C Chou³, H Dong³, Y Lizawa⁴, M Shiraishi⁴, and M Hirsch² ¹Ctr Hosp Univ Montreal, Canada; ²Massachusetts Gen Hosp, Boston, USA; ³Memorial Sloan-Kettering Cancer Ctr, New York, NY, USA; and ⁴Takeda Pharma Co, Osaka, Japan
543	Greater Synergistic Anti-HIV Effects upon Combinations of a CCR5 inhibitor AK602/ONO4128/GW873140 with CXCR4 Inhibitors than with Other Anti-HIV Drugs Hirotomo Nakata*¹, Y Koh¹, K Maeda¹, Y Takaoka², H Tamamura³, N Fujii³, and H Mitsuya^1,4 ¹Kumamoto Univ Sch of Med, Japan; ²Ono Pharma Co Ltd, Osaka, Japan; ³Grad Sch of Pharmaceutical Sci, Kyoto Univ, Sakyo-ku, Kyoto,Japan; and ⁴NCI, NIH, DHHS, Bethesda, MD, USA
544	Inhibition Mechanism of Small-molecule HIV-1 Attachment Inhibitors P F Lin*, H Ho, L Fan, C Li, B Nowicka-Sans, B McAuliff, N Zhou, R Dalterio, Y Gong, B Eggers, H Fang, T Wang, Y Ueda, and J Kadow Bristol-Myers Squibb, Wallingford, CT, USA
545	Multi-drug Resistant HIV-1 Is Sensitive to Inhibition by Chemokine Receptor Antagonists D Schols*¹, K Vermeire¹, S Fransen², W Huang², J Toma², J Whitcomb², C Petropoulos², G Calandra³, and G Bridger³ ¹Rega Inst for Med Res, Katholieke Univ, Leuven, Belgium; ²ViroLogic, Inc, South San Francisco, CA, USA; and ³AnorMED Inc, Langley, Canada
546	The V165I and T206S/S230N Mutations in HIV-1 Integrase Confer Resistance to the Pyranodipyrimidine V-165 and Reduce Replication Capacity Anke Hantson*¹, M Witvrouw¹, A Hombrouck¹, J Vercammen¹, V Tetz², C Pannecouque³, Y Engelborghs¹, E De Clercq³, and Z Debyser¹ ¹Katholieke Univ, Leuven, Belgium; ²St-Petersburg Pavlov State Med Univ, Russia; and ³Rega Inst for Med Res, Katholieke Univ, Leuven, Belgium
547	Styrylquinolines Derivatives Targeting HIV Integrase are in vitro Synergic with Reverse Transcriptase Inhibitors and Diketo Acids H Leh¹, C M Thomas¹, F Zouhiri¹, Arnaud Chéret*¹, and J F Mouscadet² ¹BioAlliance Pharma, Paris, France and ²LBPA CNRS UMR 8113 ENS, Cachan, France
548	Suppression of HIV-1 Replication and Inhibition of eIF5A Hydroxylation: Dual Effects of 2 Widely Used Drugs Deepti Saxena*¹, P Palumbo¹, H Hanauske-Abel¹, M Hoque¹, D D'Alliessie², M Park³, E Wolff³, Z Garcia¹, T Pe'ery¹, and M Mathews¹ ¹Univ of Med and Dentistry of New Jersey, Newark, USA; ²Princeton Univ, NJ, USA; and ³NIH, DHHS, Bethesda, MD, USA
549	Human Recombinant IgG₁ anti-Tat Antibodies Inhibit HIV-1 Viral Replication in vitro J Hinkula¹, Y Stenberg², C Devito¹, Elisabeth Sonesson*², G Goldstein³, and R Carlsson² ¹Swedish Inst for Infectious Disease Control, Solna; ²BioInvent Intl AB, Lund, Sweden; and ³Thymon LLC, Short Hills, NJ, USA
550	Synergistic Inhibition of HIV-1 Gene Expression by Novel Non-GUX Hammerhead Ribozymes and DNA Enzymes Targeted against Second Exon of TAT/REV of HIV Akhil C Banerjea* and H Unwalla Natl Inst of Immunology, New Delhi, India
551	The Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of PA-457, the First-in-class HIV Maturation Inhibitor, in Healthy Volunteers David Martin*¹, C Ballow², J Doto¹, R Blum², C Wild¹, and G Allaway¹ ¹Panacos Pharma, Inc, Gaithersburg, MD, USA and ²Buffalo Clin Res Ctr, NY, USA
552	Phase I Clinical Trial Demonstrates Safety and Feasibility of Autologous Cellular Therapy with Lentiviral Vector Modified CD4 T Cells Expressing Anti-HIV Antisense in Patients with HAART-resistant HIV-1 Infection Boro Dropulic*^1,2, R R MacGregor⁴, L Humeau¹, G Binder¹, X Lu¹, V Slepushkin¹, R Merling¹, M Pereira¹, T Slepushkina¹, S Barnett³, R Carroll⁵, B Levine⁵, F Bushman⁶, and C June⁵ ¹VIRxSYS Corp, Gaithersburg, MD, USA; ²Sydney Kimmel Comprehensive Cancer Ctr, Johns Hopkins Univ, Baltimore, MD, USA; ³Gary Lambert Res Ctr, Johns Hopkins Univ, Baltimore, MD, USA; ⁴Univ of Pennsylvania, Philadelphia, USA; ⁵Abramson Family Cancer Res Inst, Univ of Pennsylvania, Philadelphia, USA; and ⁶Univ of Pennsylvania, Philadelphia, USA